✦ LIBER ✦

Simulations of silicon microdosimetry measurements in fast neutron therapy

✍ Scribed by I. Cornelius; A. Rosenfeld; P. Bradley

Publisher: Springer Netherlands
Year: 2002
Tongue: English
Weight: 259 KB
Volume: 25
Category: Article
ISSN: 0158-9938
DOI: 10.1007/bf03178290

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Spectral energy measurements in a fast n

Spectral energy measurements in a fast neutron therapy field

✍ P.J. Binns; J.H. Hough 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Measurements of fast-neutron-induced sig

Measurements of fast-neutron-induced signals in silicon pad detectors

✍ V. Linhart; I. Bědajánek; P. Bém; M. Götz; M. Honusek; S. Pospís˘il; E. Šimečkov 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Radiation effects of fast neutrons in si

Radiation effects of fast neutrons in silicon diffused detectors

✍ Sachelarie, D. ;Dragan, M. ;Stoica, M. ;Sachelarie, M. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 605 KB

Measurement of fast neutrons and seconda

Measurement of fast neutrons and secondary gamma rays in graphite

✍ A.S. Makarious; I.I. Bashter; A. El-Asyed Abdo; W.A. Kansouh 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 462 KB

Investigation of Radiation Damage in Sil

Investigation of Radiation Damage in Silicon Produced by Fast Neutron Irradiation with Lifetime Measurements and Deep Level Transient Spectroscopy

✍ Stefanov, K. D. ;Hardalov, Ch.M. ;Sueva, D. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

The role of fast neutron therapy in unre

The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report

✍ Carrie, C. ;Breteau, N. ;Negrier, S. ;Frappaz, D. ;Bouffet, E. ;Thiesse, P. H. ; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

## Abstract Primary osteosarcoma of the pelvic bones represents less than 10% of all osteosarcoma. despite mutilating surgical procedures or high‐dose radiotherapy and neoadjuvant chemotherapy, local failures and distant metastases remain common. the 2‐year actuarial survival rate is less than 50%